|
|
| Thérapies > Etude de marché sectorielle |
| Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
|
|
|
|
€ 9 120,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2006 |
Taille du document : |
234 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 21 pages | Novembre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,clinical trials,toxicology,...
|
| Research
focus: |
market outlook,market size and estimates, |
| Geographic
focus: |
usa,canada,spain |
| |
|
|
|
|
| 21 pages | Octobre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,pharmaceutical,clinical trials,...,...
|
| Research
focus: |
market size and estimates,economy outlook |
| Geographic
focus: |
china,japan,india,indonesia,malaysia,singapore,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Latin American Cancer Market Outlook to 2010
173 pages | Novembre 2005 |
The patient pool for cancer therapies is rising at a higher rate than the growth rate in population across the ten Latin American pharmaceutical markets, a trend primarily driven by the rising life ex |
2 443,75 €
|
| |
| |
MarketWatch: CNS
29 pages | Octobre 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
170,00 €
|
| |
| |
Stakeholder Insight: Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
199 pages | Avril 2005 |
IntroductionAnthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer.
In recent days, however, agents such as Sanofi-Aventis's Taxotere and Astr |
9 120,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Avril 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Stakeholder Opinions: Chronic Leukemias - Curative Intent Raises the Bar
174 pages | Octobre 2005 |
IntroductionRecognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy.
I |
3 230,00 €
|
| |
| |
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
US Antidepressants 2004
12 pages | Décembre 2004 |
Snapdata's US Antidepressants 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the US antidepressant market, and |
240,00 €
|
| |
| |
Nutraceuticals - Targeting Consumers Aged 35+
154 pages | Septembre 2000 |
Not only does the 35+ consumer group account for a significant and growing percentage of the total population; it is also at the greatest risk of major illnesses.
Despite advances in medicine |
955,00 €
|
| |
| |
MarketWatch: CNS
25 pages | Février 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
160,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
|
|
Introduction
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.
Scope
Analysis of patient potential, unmet needs and clinical trial design in migraine
Overview of drugs in preregistration, Phase III, II and I; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in migraine, with forecasts of drug revenues to 2015
Discussion of GSK and Pozen's strategies and insight from key industry opinion leaders
Highlights
Due to Imitrex's commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending US sumatriptan patent expiry will limit its success.
The next big thing in the prophylactic market will be the label expansion of Allergan's Botox and Ipsen's Dysport. Seven major market Botox and Dysport combined sales for migraine are forecast to grow to over $170m in 2015.
The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP antagonists, amongst others in early stage clinical trials, indicate companies are developing innovative drugs for the post triptan future. With all identified to play a role in the biological mechanisms of migraine, there holds great potential in such novel drug targets.
Reasons to Purchase
Understand unmet needs in the migraine market based on key opinion leader comments
Benchmark key late-stage migraine compounds against current market leaders
Assess the combined US, Japan, five major EU sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
|
|
Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
|
|
PPLSEN
|
|
|
|
|
